The analysts covering CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) delivered a dose of negativity to shareholders today...
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Key Insights Institutions' substantial holdings in CytomX Therapeutics implies that they have significant influence...